文献速递产科

电针联合静脉患者自控镇痛在剖宫产术后的疗效:一项随机临床试验

Efficacy of electroacupuncture combined with intravenous patient-controlled analgesia after cesarean delivery: a randomized clinical trial.
PubMed 文献 · Am J Obstet Gynecol MFM · 2022-12-01

这项单中心、随机、单盲、假电针对照试验纳入174例剖宫产术后使用芬太尼静脉自控镇痛的初产妇,比较2 Hz电针、20/100 Hz电针与假电针的镇痛效果。电针组在术后48小时内镇痛泵按压次数、各时间点疼痛评分及芬太尼消耗量均显著低于假电针组(P<.001)。作者认为电针安全有效,可推荐作为剖宫产术后疼痛控制的常规辅助疗法。

要点

  • 电针组术后48小时镇痛泵按压次数和芬太尼消耗量均显著低于假电针组(P<.001)。
  • 电针组术后6、12、24、48小时疼痛评分均显著低于假电针组(P<.001)。
  • 作者认为电针可推荐作为剖宫产术后疼痛控制的常规辅助疗法。

核心结论

  • 电针联合静脉患者自控镇痛在剖宫产术后48小时内的镇痛效果显著优于假电针联合静脉患者自控镇痛。
  • 作者认为电针安全有效,可改善静脉患者自控镇痛在剖宫产术后疼痛管理中的效果,并可推荐作为剖宫产术后疼痛控制的常规辅助疗法。

研究设计与样本

  • 单中心、随机、单盲、假电针对照临床试验,在中国一家三级大学医院开展。
  • 纳入剖宫产术后使用芬太尼静脉患者自控镇痛的女性患者,术后随机分为2 Hz电针组(n=53)、20/100 Hz电针组(n=53)或假电针组(n=52)。
  • 电针组在ST36和SP6穴位分别接受2 Hz或20/100 Hz电针治疗,假电针组在非经络穴位使用未通电的电针仪器进行假电针。
  • 所有组均在术后6、12、24、48小时进行4次电针治疗。
  • 主要结局为术后48小时镇痛泵按压次数;次要结局包括术后6、12、24小时镇痛泵按压次数、术后6、12、24、48小时疼痛评分、术后48小时芬太尼消耗量、术后12和48小时白细胞介素6和降钙素原水平及首次排气时间。

主要发现

  • 电针治疗组在全部4个时间点的镇痛泵按压次数和疼痛评分以及术后48小时芬太尼消耗量均显著低于假电针组(P<.001)。

临床怎么用

  • 作者认为电针可推荐作为剖宫产术后疼痛控制的常规辅助疗法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Electroacupuncture is a nonpharmacologic intervention for analgesia that is widely recognized as therapy for pain. However, the clinical efficacy of electroacupuncture combined with patient-controlled intravenous analgesia for postoperative analgesia after cesarean delivery remains unclear. OBJECTIVE: This study aimed to assess the efficacy of electroacupuncture + patient-controlled intravenous analgesia for postoperative analgesia after cesarean delivery, determine the optimal frequency for the best analgesic effect, and explore the underlying mechanism of action. STUDY DESIGN: This single-center, randomized, single-blinded, sham acupuncture controlled clinical trial was conducted at a tertiary university hospital in China. Female patients who underwent cesarean delivery and received fentanyl as patient-controlled intravenous analgesia for postoperative analgesia were enrolled. Patients were after surgery randomized to receive 2 Hz electroacupuncture treatment (n=53), 20/100 Hz electroacupuncture treatment (n=53), or sham electroacupuncture treatment (n=52) (controls). The 2 electroacupuncture groups received electroacupuncture treatment at 2 or 20/100 Hz at the ST36 and SP6 points, whereas, in the sham electroacupuncture group, sham electroacupuncture was performed at nonmeridian points with nonenergized electroacupuncture instruments. Of note, 4 electroacupuncture treatments were performed in all groups at 6, 12, 24, and 48 hours after surgery. The primary outcome was the number of analgesic pump compressions at 48 hours after surgery. The secondary outcomes included number of analgesic pump compressions at 6, 12, and 24 hours after surgery; pain scores at 6, 12, 24, and 48 hours after surgery; fentanyl consumption at 48 hours after surgery; interleukin 6 and procalcitonin levels at 12 and 48 hours after surgery; and time to first exhaust. RESULTS: Overall, 174 primigravida women were included in the intention-to-treat analysis. The number of analgesic pump compressions and pain scores at all 4 time points and fentanyl consumption at 48 hours after surgery were significantly lower in the electroacupuncture treatment groups than in the sham electroacupuncture group (P<.001). CONCLUSION: Electroacupuncture + patient-controlled intravenous analgesia had a significantly better analgesic effect than sham electroacupuncture + patient-controlled intravenous analgesia within 48 hours after surgery. Thus, electroacupuncture can be considered safe and effective and may improve the efficacy of patient-controlled intravenous analgesia for pain management after cesarean delivery. Electroacupuncture can be recommended as a routine complementary therapy for pain control after cesarean delivery.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Jin Y, Yu X, Hu S, et al. Efficacy of electroacupuncture combined with intravenous patient-controlled analgesia after cesarean delivery: a randomized clinical trial. Am J Obstet Gynecol MFM. 2022. PMID: 36464237. doi:10.1016/j.ajogmf.2022.100826

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。